Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals (Nasdaq:LXRX) reported second quarter 2026 revenues of $0.7 million, down from $28.9 million a year earlier, reflecting the absence of prior-period Novo Nordisk licensing revenue. The company posted a net loss of $31.8 million, or $0.07 per share, versus net income of $3.3 million, or $0.01 per share, in 2025.
R&D expenses rose to $17.4 million and SG&A to $9.8 million. Cash and investments increased to $190.6 million, aided by $96.2 million of February equity proceeds and a new $100 million Hercules Capital loan facility, of which $55 million was drawn to refinance prior debt.
Lexicon completed enrollment of the >500-patient Phase 3 SONATA-HCM study of sotagliflozin, with topline data expected in Q1 2027, and plans an NDA resubmission for ZYNQUISTA in type 1 diabetes in Q4 2026. Novo Nordisk’s Phase 1 obesity program for LX9851 is ongoing, with Lexicon eligible for up to $1 billion in milestones plus royalties.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to review results and provide a business update.
According to Lexicon, investors can access the live webcast via the Events page of its investor website, with separate registration required to receive dial-in details for asking questions. An archived webcast will be available. Lexicon is a biopharmaceutical company with drug candidates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and other cardiometabolic indications.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced completion of patient randomization in the pivotal Phase 3 SONATA-HCM trial of sotagliflozin in symptomatic non-obstructive (nHCM) and obstructive (oHCM) hypertrophic cardiomyopathy. The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries.
The final population includes a substantial majority of nHCM patients and a meaningful oHCM cohort. The randomized, double-blind, placebo-controlled trial evaluates symptoms, function, patient-reported outcomes and safety, with the primary endpoint being change from baseline to week 26 in KCCQ Clinical Summary Score. Topline results are anticipated in Q1 2027.
Lexicon (Nasdaq:LXRX) will present new clinical data at the American Diabetes Association (ADA) 2026 Scientific Sessions, June 5-8 in New Orleans.
Posters will cover sotagliflozin in type 1 diabetes, highlighting consistent A1c reductions, and pilavapadin pharmacokinetics across renal function groups.
Lexicon Pharmaceuticals (Nasdaq:LXRX) announced that company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 p.m. ET in New York City.
The live event and replay will be available via the Events page of Lexicon's investor website.
Lexicon Pharmaceuticals (Nasdaq:LXRX) announced that management will take part in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq World Headquarters in New York City on May 19, 2026. A live webcast and replay will be available on the company’s investor relations Events page.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q1 2026 results and pipeline updates on May 7, 2026. Key points: Total revenue $21.1M (including a $20.0M Novo Nordisk milestone), cash, investments and restricted cash $199.7M, and a $100M Hercules loan facility with $55M funded.
Clinical highlights: SONATA-HCM enrollment expected mid-2026, potential NDA resubmission for ZYNQUISTA mid-2026, and Novo Nordisk initiated Phase 1 for LX9851.
Lexicon Pharmaceuticals (NASDAQ: LXRX) entered a loan facility with Hercules Capital providing up to $100 million in borrowing capacity, with an initial $55 million funded at closing to repay an existing facility. The facility includes two optional tranches of $20 million and $25 million, a floating rate (prime +3.1%, floor 9.85%), an 18-month interest-only period (two six-month extension options), and maturity by May 4, 2030. Obligations are secured by a first lien on assets and include customary covenants and a minimum cash covenant effective June 1, 2027.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will report first quarter 2026 financial results on May 7, 2026 before the market opens. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to discuss results and provide a business update.
Access the live webcast via the company Events page and use the dial-in to ask questions; an archived webcast will be posted after the call.
Lexicon (NASDAQ:LXRX) will present Phase 2b and preclinical data at the American Academy of Neurology Annual Meeting, April 18-22, 2026 in Chicago.
Key points: PROGRESS data support selection of pilavapadin 10 mg for Phase 3 in diabetic peripheral neuropathic pain after a nominally significant reduction in Average Pain at Week 8 and concordant improvements in Worst and Least Daily Pain. The 10 mg dose was generally well-tolerated over 8 weeks. Lexicon will also present preclinical spasticity data on April 20.